Barclays’s BridgeBio Pharma BBIO Stock Holding History

Barclays’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Hold	20,400	–	–	﹤0.01%	2524
2026 Q1	$1.51M	Hold	20,400	–	–	﹤0.01%	2519
2025 Q4	$1.56M	Hold	20,400	–	–	﹤0.01%	3105
2025 Q3	$1.06M	Buy	+20,400	New	+$995K	﹤0.01%	3328
2024 Q2	–	Sell	-36,500	Closed	-$1.13M	–	4877
2024 Q1	$1.13M	Buy	36,500 +30,000	+462%	+$1.02M	﹤0.01%	3022
2023 Q4	$262K	Buy	+6,500	New	+$195K	﹤0.01%	4292

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Barclays's BBIO Position: Q2 2026 in Review

Barclays increased its BridgeBio Pharma (BBIO) stake by 69% in Q2 2026, buying an estimated $20.3M and bringing the position to 714,423 shares worth $53.2M. The position accounts for 0.01% of the portfolio, ranked #710.

Barclays first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Barclays held 714,423 shares of BridgeBio Pharma worth $53.2M as of Q2 2026.
Barclays bought 290,535 BridgeBio Pharma shares in Q2 2026, an estimated $20.3M.
BridgeBio Pharma made up 0.01% of Barclays's portfolio in Q2 2026, its #710 holding.
Barclays first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.